DY
University of Washington
Repurposes colchicine against MYH7 dilated cardiomyopathy by restoring the MEF2C-desmin axis.
Get the Discover digest
Receive a weekly email digest of the latest cardiovascular health solutions added by the network.Get the Discover digest
Receive a weekly email digest of the latest cardiovascular health solutions added by the network.Updated Sept 30, 2026
Cardiovascular health covers the therapies, models and tissue resources used against heart and vascular disease. On Halo, the solutions cover genetic cardiomyopathy therapeutics, patient-derived cardiac cells and tissue banks, thrombosis and vascular models, and cardiometabolic prevention. Sign up to search the full network and post your specific need.
DY
University of Washington
Repurposes colchicine against MYH7 dilated cardiomyopathy by restoring the MEF2C-desmin axis.
AAV9-delivered RNA interference against CSTF64, aimed at cutting cardiac fibrosis in heart failure.
Maastricht University
Maps the altered kinome in LMNA-related cardiomyopathy to find a druggable pathway.
University of Amsterdam
Builds therapies for genetically derived cardiomyopathies on patient-derived iPSCs.
Targets desmin-related dilated cardiomyopathy using engineered heart tissue from patient stem cells.
Technion - Israel Institute of Technology
iPSC-derived cardiomyocytes carrying the patient's own cardiomyopathy mutation, for testing candidates.
Fraunhofer Institute
A supply of hiPSC cardiomyocytes with known cardiomyopathy mutations, offered for collaboration.
Sapphiros AiBio
A bank of more than 85,000 human cell lines, including cardiomyopathy and Long QT lines.
University of Kentucky
Human heart tissue from end-stage disease, collected for research use.
University of British Columbia
Uses explanted diseased hearts to map therapeutic targets and predict how candidates will behave.
LU
University of Alberta
An in vivo rabbit model for testing anti-thrombotic candidates against bleeding time.
AL
Michigan State University
A rabbit model chosen for platelet biology close to human, for antithrombotic efficacy and safety.
University of California, San Diego
A rabbit model of cerebral venous sinus thrombosis induced with ferric chloride.
Sign up free to search the full network and post your specific need.
Already have an account?
Universities, startups, and suppliers with solutions in cardiovascular health.
Cardiovascular health organizationsResearchers and inventors advancing cardiovascular health.
Cardiovascular health expertsCardiovascular health on Halo runs from the genetics of a named cardiomyopathy through to the preclinical models a program needs before it can test anything in people. On Halo it spans five groups, including genetic cardiomyopathy therapeutics, patient-derived cardiac cells and tissue banks, and thrombosis and vascular models.
Stage of development. Work on cardiovascular health on Halo comes mostly from university programs. 30% of the solutions are in market. Co-development and sponsored research are the usual partnering routes, and about 39% of the solutions that state terms offer pilot engagements.
Therapies aimed at one mutation. These programs name the gene and not the syndrome. One repurposes colchicine against MYH7 dilated cardiomyopathy; another maps the kinome altered in LMNA-related disease. The work is narrower than heart failure and closer to the patients it would treat.
Patient-derived cardiac cells. Several groups now offer cardiomyocytes carrying a patient's own cardiomyopathy mutation, and one bank holds more than 85,000 human cell lines including Long QT. A candidate can be tested against the genotype it is meant for before any animal work.
Prevention through metabolism. A second cluster treats cardiovascular risk as a metabolic problem. One team screens postbiotics that block a gut microbial conversion tied to cardiac risk; another optimizes micronutrient profiles for cardiometabolic health using systematic review and machine learning.
Cardiovascular health covers the therapies, diagnostics and research models aimed at the heart and the blood vessels. It spans gene-specific cardiomyopathy programs, antithrombotic agents, cardiometabolic prevention, and the cell and tissue resources used to test any of them before a patient is involved. Pharmaceutical developers, device makers and academic cardiology groups do the work.
Five examples of cardiovascular health solutions on Halo include:
The most recently updated cardiovascular health solutions on Halo include:
There are 308 organizations with cardiovascular health solutions on Halo, 62 of them universities and research institutions. Among them are University of Washington, Houston Methodist, and Maastricht University. Most offer co-development or sponsored research. Sign up to see every organization working in the area and to send them your specific need.
Browsing cardiovascular health solutions on Halo is free. Sign up to search the full network and save the ones you want. Post your specific need to get exact matches. Organizations reply directly on the platform.
Confirm digest type